Analyst firms · Morgan Stanley · HALO

Morgan Stanley HALO price target and rating history

Halozyme Therapeutics Inc. (HALO) · Health Care

Morgan Stanley rates Halozyme Therapeutics Inc. (HALO) Equal-Weight with a $109 price target, as of its latest action on Nov 11, 2026. It has published 5 rating actions on HALO since September 2022, including 1 upgrade and 2 downgrades. Across 3 firms with a HALO price target in the last 12 months, the median target is $109. Morgan Stanley's target matches it.

Current rating
Equal-Weight
Price target
$109
Median target, all firms
$109
Actions on HALO
5

Morgan Stanley price target on HALO

$109$80$502023202420252026
Morgan Stanley price target on HALO, each point a stated target, September 2022 to November 2026.

Every Morgan Stanley rating on HALO

How other firms rate HALO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Morgan StanleyEqual-Weight$109Nov 11, 2026
Leerink PartnersOutperform$110Aug 7, 2026
Goldman SachsSell$56Dec 4, 2025

Questions about Morgan Stanley and HALO

What is Morgan Stanley's price target for HALO?
Morgan Stanley's latest stated price target for Halozyme Therapeutics Inc. (HALO) is $109, from its action on Nov 11, 2026.
What is Morgan Stanley's rating on HALO?
Morgan Stanley rates HALO Equal-Weight, a neutral rating, as of Nov 11, 2026.
When did Morgan Stanley last change its view on HALO?
On Nov 11, 2026, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $109.
How does Morgan Stanley's HALO target compare with other analysts?
Across 3 firms with a HALO price target in the last 12 months, the median target is $109. Morgan Stanley's target matches it.

More HALO rating histories

All Morgan Stanley ratingsHALO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.